Financial Performance - The group's revenue decreased by 3.2% from RMB 1,405.5 million for the year ended December 31, 2024, to RMB 1,360.4 million for the year ended December 31, 2025[2]. - The group's profit before tax decreased by 2.5% from RMB 262.7 million to RMB 256.1 million, with a profit before tax margin increasing from 18.7% to 18.8%[2]. - The net profit decreased by 4.7% from RMB 186.2 million to RMB 177.4 million, with a net profit margin decreasing from 13.2% to 13.0%[2]. - The adjusted net profit under non-IFRS decreased by 7.3% from RMB 202.7 million to RMB 187.9 million, with the adjusted net profit margin decreasing from 14.4% to 13.8%[3]. - The gross profit margin decreased from 43.5% to 42.2%[7]. - The EBITDA under non-IFRS for the year ended December 31, 2025, was RMB 363.2 million, compared to RMB 374.1 million for the previous year[7]. - Revenue from consumer ophthalmic services decreased by 2.4% from RMB 706.4 million for the year ending December 31, 2024, to RMB 689.5 million for the year ending December 31, 2025, primarily due to pricing adjustments in response to intensified market competition[25]. - Revenue from basic ophthalmic services decreased by 4.3% from RMB 697.8 million for the year ending December 31, 2024, to RMB 667.6 million for the year ending December 31, 2025, mainly due to the impact of national medical insurance pricing reforms[28]. - Gross profit decreased by 6.1% from RMB 611.3 million for the year ending December 31, 2024, to RMB 573.9 million for the year ending December 31, 2025, with gross margin declining from 43.5% to 42.2%[30]. Operational Metrics - The number of ophthalmology hospitals and optical centers operated by the group increased to 31 and 32, respectively, with an increase of three optical centers compared to the previous year[4]. - Outpatient visits decreased from 1,137,742 in 2024 to 1,061,851 in 2025, while the average spending per visit increased from RMB 713 to RMB 764[9]. - Inpatient visits decreased from 72,120 in 2024 to 69,747 in 2025, with the average spending per visit decreasing from RMB 6,914 to RMB 6,354[9]. - The consumer ophthalmology services segment generated revenue of RMB 689.5 million in 2025, accounting for 50.7% of total revenue, compared to RMB 706.4 million and 50.3% in 2024[11]. - The basic ophthalmology services segment generated revenue of RMB 667.6 million in 2025, accounting for 49.1% of total revenue, down from RMB 697.8 million and 49.6% in 2024[11]. Expenses and Costs - The total operating expenses, including selling and administrative expenses, were RMB 377.6 million for the year ended December 31, 2025[7]. - Selling and distribution expenses decreased by 11.3% from RMB 124.6 million for the year ending December 31, 2024, to RMB 110.5 million for the year ending December 31, 2025, mainly due to reduced compensation for sales and marketing personnel[33]. - Administrative expenses decreased by 7.7% from RMB 237.5 million for the year ending December 31, 2024, to RMB 219.1 million for the year ending December 31, 2025, primarily due to the end of share-based payment amortization for certain management personnel[34]. - Financing costs increased by 14.0% from RMB 10.7 million for the year ending December 31, 2024, to RMB 12.2 million for the year ending December 31, 2025, mainly due to interest expenses from convertible bonds issued in December 2024[36]. - Income tax expenses increased by 2.9% from RMB 76.5 million for the year ending December 31, 2024, to RMB 78.7 million for the year ending December 31, 2025, primarily due to an increase in unrecognized deferred tax asset losses[37]. Strategic Initiatives - The company aims to expand its network across seven provinces and municipalities in China, providing a range of ophthalmic services and products[8]. - The company continues to invest in advanced ophthalmic equipment and new technologies to enhance service quality and patient safety, including the introduction of femtosecond laser-assisted cataract surgery equipment[15]. - The company is focusing on optimizing marketing activities, particularly through online channels, and enhancing patient management to maintain customer loyalty[13]. - The group plans to continue expanding its network in North China and aims to acquire and establish more hospitals and optical centers in the near future[21]. - The company has a plan to fully utilize the funds for establishing new hospitals by December 31, 2027[70]. Employee and Governance - As of December 31, 2025, the group has a total of 1,474 full-time medical professionals, including 324 doctors, 620 nurses, and 530 other professionals[17]. - The company has implemented a share incentive plan to reward and retain employees, effective from May 10, 2022[77]. - The company provides systematic training and education programs to ensure high-quality service delivery by its employees[78]. - The company has established an audit committee to provide independent opinions on financial reporting procedures and internal controls[67]. - The board of directors includes Chairman and Executive Director Mr. Zhang Bozhou, Executive Directors Ms. Zhang Xiaoli, Mr. Zhang Junfeng, and Mr. Zhang Guangdi[127]. Cash Flow and Investments - Cash and cash equivalents decreased by RMB 264.4 million in 2025, primarily due to net cash inflow from operating activities of RMB 339.4 million and net cash outflow from investing activities of RMB 460.6 million[45]. - The net cash flow from investing activities for 2025 was RMB (460.6) million, indicating significant capital expenditures[45]. - The company has no significant contingent liabilities or guarantees as of December 31, 2025[48]. - The company raised approximately HKD 1,599 million from its global offering, issuing 137,500,000 shares at HKD 10.60 each, with an additional 20,125,000 shares issued after the exercise of the over-allotment option[68]. - The company has allocated approximately HKD 90.31 million for upgrading its information technology systems[69]. Market Position and Recognition - The group has received various awards and recognitions in 2025, including being named a "National Civilized Unit" and receiving the "Outstanding Unit for Medical Service Capability Improvement" honor[18]. - The group is committed to providing charitable medical assistance and diagnostic services to vulnerable communities, enhancing its brand reputation[19]. - The group is involved in various charitable activities, including providing eye examinations and treatments for underprivileged groups[20]. - The group aims to strengthen its leading position in North China and improve its market position in key regions such as the Yangtze River Delta[23]. Future Outlook - The company plans to continue focusing on cost management and exploring new market opportunities to enhance future performance[87]. - The company has not identified any significant future investment or capital asset plans disclosed as of December 31, 2025[57].
朝聚眼科(02219) - 2025 - 年度业绩